Literature DB >> 6456892

Anomalous effect of serum on the antimicrobial activity of cefoperazone.

S D Lang, G L Cameron, P R Mullins.   

Abstract

This study investigated the effect of added serum on cefoperazone activity in vitro. Due to protein-binding, an 8-fold difference would be expected between minimum inhibitory concentrations in broth and in broth plus 90% serum. Using supplemented Mueller-Hinton broth (sMH) and sMH plus 90% heat-inactivated human serum there were differences of 3.36 +/- 0.92 for Staphylococcus aureus strain ATCC1 25923, 1.39 +/- 0.47 for Escherichia coli strain ATCC 25922 and 1.43 +/- 0.39 for Pseudomonas aeruginosa strain ATCC 27853. Serum-related modal increases in minimum inhibitory concentrations of cefoperazone for clinical isolates were 4-fold versus Staphylococcus aureus (5 strains), Klebsiella species (5 strains) and Pseudomonas aeruginosa (8 strains), and 2-fold versus Escherichia coli (4 strains). On the addition of serum to 2 strains of Serratia marcescens, divergent effects were seen. Minimum lethal concentrations of cefoperazone were generally identical to, or a low multiple of, corresponding minimum inhibitory concentrations. Variables other than protein binding may account for the anomalous activity of antibiotics against organisms in serum. These factors favour the activity of cefoperazone against several clinically important species.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6456892     DOI: 10.2165/00003495-198100221-00012

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  21 in total

1.  Demethylchlortetracycline and tetracycline. A critical comparison: in vitro activity, serum concentrations, and effect of serum binding.

Authors:  C E ROBERTS; D M PERRY; H A KUHARIC; W M KIRBY
Journal:  Arch Intern Med       Date:  1961-02

2.  The interactions of drugs and plasma proteins.

Authors:  A GOLDSTEIN
Journal:  J Pharmacol Exp Ther       Date:  1949-04       Impact factor: 4.030

3.  Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent.

Authors:  C W Stratton; L B Reller
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

4.  Cefoperazone: absorption, excretion, distribution, and metabolism.

Authors:  K Shimizu
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

5.  Single-dose pharmacokinetics of cefoperazone following intravenous administration.

Authors:  W A Craig
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

Review 6.  Clinical significance of protein binding of the penicillins.

Authors:  C M Kunin
Journal:  Ann N Y Acad Sci       Date:  1967-09-27       Impact factor: 5.691

7.  Pharmacokinetics of cephalosporin antibiotics: protein-binding considerations.

Authors:  S M Singhvi; A F Heald; E C Schreiber
Journal:  Chemotherapy       Date:  1978       Impact factor: 2.544

8.  Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli.

Authors:  S D Lang; D J Edwards; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

9.  Studies on protein binding of antibiotics. I. Effect of cefazolin on protein binding and pharmacokinetics of cefoperazone.

Authors:  Y Watanabe; T Hayashi; R Takada; T Yasuda; I Saikawa; K Shimizu
Journal:  J Antibiot (Tokyo)       Date:  1980-06       Impact factor: 2.649

10.  Rational choice of penicillins and cephalosporins based on parallel in-vitro and in-vivo tests.

Authors:  S Selwyn
Journal:  Lancet       Date:  1976-09-18       Impact factor: 79.321

View more
  13 in total

1.  Effect of ertapenem protein binding on killing of bacteria.

Authors:  David E Nix; Kathryn R Matthias; Emily C Ferguson
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  A model of cefoperazone tissue penetration: diffusion coefficient and protein binding.

Authors:  A Meulemans
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  Effect of protein binding on the pharmacological activity of highly bound antibiotics.

Authors:  Stephan Schmidt; Katharina Röck; Martina Sahre; Olaf Burkhardt; Martin Brunner; Maximilian T Lobmeyer; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

4.  Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.

Authors:  G G Zhanel; I D Kirkpatrick; D J Hoban; A M Kabani; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 5.  Role of pharmacokinetics in the outcome of infections.

Authors:  G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

6.  Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers.

Authors:  Y W Lam; M H Duroux; J G Gambertoglio; S L Barriere; B J Guglielmo
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

Review 7.  Seventy-Five Years of Research on Protein Binding.

Authors:  Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

8.  Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram-negative bacilli.

Authors:  J E Leggett; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

9.  Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum.

Authors:  H Pruul; P J McDonald
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

10.  Cefdinir-induced modification of the susceptibility of bacteria to the antibacterial activity of human serum and polymorphonuclear neutrophils.

Authors:  H Pruul; P J McDonald
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-03       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.